The Journal of Neuroscience, January 21, 2009, 29(3):653-668; doi:10.1523/JNEUROSCI.3814-08.2009
Previous Article | Next Article 
Cellular/Molecular
Non-Nuclear WldS Determines Its Neuroprotective Efficacy for Axons and Synapses In Vivo
Bogdan Beirowski,1
Elisabetta Babetto,1
Jon Gilley,1
Francesca Mazzola,2
Laura Conforti,1
Lucie Janeckova,1
Giulio Magni,2
Richard R. Ribchester,3 and
Michael P. Coleman1
1Laboratory of Molecular Signalling, The Babraham Institute, Cambridge CB22 3AT, United Kingdom, 2Institute of Biochemical Biotechnologies, University of Ancona, Via Ranieri, 60131 Ancona, Italy, and 3Centre for Neuroscience Research, University of Edinburgh, Edinburgh EH8 9JZ, United Kingdom
Correspondence should be addressed to Dr. Michael P. Coleman, Laboratory of Molecular Signalling, The Babraham Institute, Babraham Research Campus, Babraham, Cambridge CB22 3AT, UK. Email: michael.coleman{at}bbsrc.ac.uk
Axon degeneration contributes widely to neurodegenerative disease but its regulation is poorly understood. The Wallerian degeneration slow (WldS) protein protects axons dose-dependently in many circumstances but is paradoxically abundant in nuclei. To test the hypothesis that WldS acts within nuclei in vivo, we redistributed it from nucleus to cytoplasm in transgenic mice. Surprisingly, instead of weakening the phenotype as expected, extranuclear WldS significantly enhanced structural and functional preservation of transected distal axons and their synapses. In contrast to native WldS mutants, distal axon stumps remained continuous and ultrastructurally intact up to 7 weeks after injury and motor nerve terminals were robustly preserved even in older mice, remaining functional for 6 d. Moreover, we detect extranuclear WldS for the first time in vivo, and higher axoplasmic levels in transgenic mice with WldS redistribution. Cytoplasmic WldS fractionated predominantly with mitochondria and microsomes. We conclude that WldS can act in one or more non-nuclear compartments to protect axons and synapses, and that molecular changes can enhance its therapeutic potential.
Key words: axon degeneration; Wallerian degeneration; neurodegeneration; slow Wallerian degeneration gene; neuroprotection; neuromuscular junction
Received Aug. 11, 2008;
revised Nov. 8, 2008;
accepted Dec. 4, 2008.
Correspondence should be addressed to Dr. Michael P. Coleman, Laboratory of Molecular Signalling, The Babraham Institute, Babraham Research Campus, Babraham, Cambridge CB22 3AT, UK. Email: michael.coleman{at}bbsrc.ac.uk
This article has been cited by other articles:

|
 |

|
 |
 
Y. Sasaki, B. P. S. Vohra, R. H. Baloh, and J. Milbrandt
Transgenic Mice Expressing the Nmnat1 Protein Manifest Robust Delay in Axonal Degeneration In Vivo
J. Neurosci.,
May 20, 2009;
29(20):
6526 - 6534.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Conforti, A. Wilbrey, G. Morreale, L. Janeckova, B. Beirowski, R. Adalbert, F. Mazzola, M. Di Stefano, R. Hartley, E. Babetto, et al.
WldS protein requires Nmnat activity and a short N-terminal sequence to protect axons in mice
J. Cell Biol.,
February 23, 2009;
184(4):
491 - 500.
[Abstract]
[Full Text]
[PDF]
|
 |
|